Related Experiment Video
Updated: Aug 2, 2026
Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
Atherectomy plus stenting: what do we gain?
1Lenox Hill Heart and Vascular Institute, NY, USA. Imoussa@worldnet.att.net
Insights
Directional atherectomy before coronary stenting may reduce in-stent restenosis in complex lesions. Further research and device improvements are needed to confirm its clinical utility for high-risk patients.
Area of Science:
- Interventional Cardiology
- Biomedical Engineering
Background:
- Coronary stents improve outcomes but can lead to in-stent restenosis, especially in complex lesions.
- High plaque burden is a key factor inciting neo-intimal proliferation post-stenting.
Purpose of the Study:
- To evaluate plaque removal via directional atherectomy as a strategy to reduce in-stent restenosis.
- To identify patient subgroups and technical factors that may optimize this approach.
Main Methods:
- Prospective non-randomized study evaluating directional atherectomy prior to stent implantation.
- Analysis of factors influencing restenosis and clinical outcomes.
Main Results:
- Prospective data suggest directional atherectomy is a promising approach for selected patients.
- Randomized trial data are pending to establish definitive proof of concept.
Conclusions:
- Directional atherectomy may reduce restenosis in specific complex coronary lesions.
- Clinical utility depends on device improvement, minimizing complications, and patient selection for high-risk scenarios.
Abstract:
Coronary stents have improved the short and long-term outcomes of selected patients undergoing catheter-based coronary interventions. However, the use of these devices in complex coronary lesions has also created an incessant form of in-stent restenosis that still defies treatment. Plaque burden has been recognized as an important factor that may incite neo-intimal proliferation after stent implantation. Prospective non-randomized experience has shown that plaque removal prior to stent implantation using directional atherectomy is a promising approach to reduce restenosis in selected patients. However, the proof of concept awaits the results of the randomized trials. Ultimately, the clinical utility of this approach will depend upon: (1) further improvements on the current directional atherectomy device; (2) minimizing the incidence of non-Q-wave myocardial infarction with selective use of IIb-IIIa platelet receptor antagonists or distal protection devices; (3) targeting patients at high risk for restenosis in whom efficient debulking is feasible such as non-calcified lesions in vessels >2.75 mm and <3.5 mm in diameter that require long stents, aorto-ostial lesions, bifurcational lesions, and chronic total occlusions.
